Transcript
Management of recurrent and refractory germ cell tumors
• Good risk GCTs achieve a very good long term cure approaching 95%
• Poor-risk GCTs require four cycles of BEP that attains an approximately 45% long-term disease-free survival
• A significant proportion are either refractory to the platinum first line chemo regimens,,or the relapse early
Standard guidelines for advanced disease
Management for residual disease
What does the NCCN say?
Therapy for early relapse and refractory disease
Salvage regimens…
VeIP/VIP
Results..
• N : 135• 49.6 % pts achieved dis. free status after
chemotherapy ( with or without surgery for residual)
• 32% are alive• 23.7% are continually free of disease• All pts had a minimal f/u of 6 yrs from entry
into study
Variable No of pts Percentage %Assessable 56 n/aResponse
CR 20 36IR 36 64
Status..Alive disease free 19 34Alive with disease 4 7
Dead 33 59Alive, continuously
disease free13 23
• N : 189 ( 1985 to 2012)• CR: 18.5%• Marker normalization: 35.4%• 2yr PFS: 34.3%• 5yr OS: 42.1%
Contribution of gemcitabine…
Prognostic factors with salvage chemo
Outcomes with second-line salvage therapy for recurrent germ cell tumors.
Sonpavde G et al. The Oncologist 2007;12:51-61
©2007 by AlphaMed Press
Role of HDCT and auto BMT?
Indiana university experience..
• Pts included:– Those , who received high dose chemotherpay as
salvage and has not progressed within 4 weeks after the last dose
• Stem cells were harvested with GCSF stimulation• High dose chemo was given with
– Carboplatin 700mg/m2– Etoposide 750mg/m2– On days -5, -4 and -3 of stem cell infusion
German data..
• N : 74pts• ORR : 63% with CR in 31%• EFS of sensitive disease at 2 yrs: 50%• Only one pt of 23 who had refractory disease
had 7mo event free survival• OS at 2 yrs: 44%
Other European data..
• N: 150• Median follow up : 55months• EFS: 29%• OS: 29%
• N: 80• 3 # TIP followed by HDCT• 70% responded to TIP• 66% responded to HDCT• 3 yr OS: 30%• 3 yr EFS: 25%
Italian experience.
• N : 84• Median follow up 46months• DFS rates:
– Good risk: 69%– Int. risk: 13%– Poor risk: 0%
High dose chemo: blessing or a curse??
Design..
• 280 pts
• Pts refractory to platinum based chemo were excluded
four cycles of cisplatin, ifosfamide
and etoposide (or vinblastine)
three such cycles followed by transplant
Roles of surgery??
• N: 125 pts who underwent postchemotherapeutic resention
• Mean f/u: 120monthns• 57% long term survivors who had raised TM• Conslusion: salvage surgery results in long
term survival of more than 50%
• N : 16pts• Six patients (37%) are alive and free of disease
at a mean of seventy-four months following surgery (range 20 to 145 months).
• Five had RP disease only. • Ten patients died of disease at a mean of eight
months postoperatively (range 5 to 21 months).
• N: 114• 5 yr OS: 53.9%• Sixty-one patients (53.5%) are alive with a medium
follow-up of 72 months• Retroperitoneal pathology revealed
– germ cell cancer in 53.5% of patients, – teratoma in 34.2% of patients, and – fibrosis in 12.2% of patients, with – 5-year survival rates of 31.4%, 77.5%, and 85.7%,
respectively (P < .0001).
Surgery after HDCT and auto BMT
• Complete resection in 93% pts• Pts with viable tumor had poor survival
comapred to teratomas or fibrosis
Therapy of late relapses
• Defn: relapses occurring after 2 yrs and in the absence of a second primary tumor
• Typically chemo refractory• Different disease biology
• N: 83• Indiana university• Available specimens were
investigated for expression of the transcription regulator FoxD3 and apurinic/apyrimidinic endonuclease and the presence of chromosome 12 abnormalities.
Results…
• Forty-three of 49 patients who underwent surgery were rendered disease free (NED), and 20 (46.5%) remain continuously NED
• Thirty-two patients received chemotherapy, but only six (18.8%) obtained a complete remission.
• Eighteen of these 32 patients were successfully rendered NED by postchemotherapy surgery, and 12 remain continuously NED.
Overall..
• 69 of the 81 treated patients (85.2%) ultimately achieved an NED state, and – 38 (46.9%) remain continuously NED with median
follow-up from LR therapy of 24.5 months (range, 1 to 83 months),
– whereas nine other patients are currently NED after therapy for subsequent relapses
– Conclusion on moleular markers could not be made i/v/o low no. of samples tested
• Follow up of 530pts
• 25 cases of late relapse identified
• Risk was lower with good risk pts
Characteristics of relapse..
• Median survival 23.9mo• Median follow up 50.3months• Only 9 survivors• CRs were observed with only TIP regimen
To summarize..
• Refractory disease and early relapse to be managed in same lines with salvage chemo +/- surgery
• HDCT with auto BMT also has shown promising results
• Later relapse:– Poor prognosis– Surgical resection whenever feasible– Chemo has poor outcomes
top related